DOCSLIB.ORG

Data Set 1. Biological Analysis of the Genes Found to Be Significant in the Endotoxin Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Data Set 1. Biological Analysis of the Genes Found to Be Significant in the Endotoxin Study Data Set 1. Biological analysis of the genes found to be significant in the endotoxin study. Pages 2 – 105: Q values, gene names and annotation on the genes significant at FDR = 0.1%. Pages 106 – 127: Global functional analysis of the down-regulated genes. Pages 128 – 169: Global functional analysis of the up-regulated genes. Probe Set q-value Direction Gene Annotation 117_at 9.60E-05 up HSPA6 heat shock 70kDa protein 6 (HSP70B') 1405_i_at 2.00E-06 down CCL5 chemokine (C-C motif) ligand 5 PRP8 pre-mRNA processing factor 8 200000_s_at 2.50E-05 down PRPF8 homolog (yeast) PRP8 pre-mRNA processing factor 8 200000_s_at 0.000712 down PRPF8 homolog (yeast) 200001_at 0.000658 down CAPNS1 calpain, small subunit 1 200002_at 2.00E-06 down RPL35 ribosomal protein L35 200002_at 2.00E-06 down RPL35 ribosomal protein L35 200003_s_at 1.10E-05 down RPL28 ribosomal protein L28 200003_s_at 1.10E-05 down RPL28 ribosomal protein L28 eukaryotic translation initiation factor 3, 200005_at 2.00E-06 down EIF3S7 subunit 7 zeta, 66/67kDa eukaryotic translation initiation factor 3, 200005_at 2.00E-06 down EIF3S7 subunit 7 zeta, 66/67kDa Parkinson disease (autosomal 200006_at 4.70E-05 down PARK7 recessive, early onset) 7 Parkinson disease (autosomal 200006_at 8.70E-05 down PARK7 recessive, early onset) 7 200008_s_at 5.40E-05 up GDI2 GDP dissociation inhibitor 2 200008_s_at 0.000361 up GDI2 GDP dissociation inhibitor 2 200009_at 0.000171 down GDI2 GDP dissociation inhibitor 2 200010_at 2.00E-06 down RPL11 ribosomal protein L11 200010_at 2.00E-06 down RPL11 ribosomal protein L11 200012_x_at 2.00E-06 down 200012_x_at 2.00E-06 down 200013_at 2.00E-06 down MAMDC2 MAM domain containing 2 200013_at 2.00E-06 down MAMDC2 MAM domain containing 2 neural precursor cell expressed, 200015_s_at 2.80E-05 down NEDD5 developmentally down-regulated 5 neural precursor cell expressed, 200015_s_at 0.000169 down NEDD5 developmentally down-regulated 5 heterogeneous nuclear 200016_x_at 2.00E-06 down HNRPA1 ribonucleoprotein A1 heterogeneous nuclear 200016_x_at 2.00E-06 down HNRPA1 ribonucleoprotein A1 200017_at 2.00E-06 down RPS27A ribosomal protein S27a 200017_at 1.10E-05 down RPS27A ribosomal protein S27a 200018_at 2.00E-06 down RPS13 ribosomal protein S13 200018_at 2.00E-06 down RPS13 ribosomal protein S13 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal 200019_s_at 2.00E-06 down FAU protein S30 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal 200019_s_at 2.90E-05 down FAU protein S30 200020_at 9.20E-05 down TARDBP TAR DNA binding protein 200022_at 2.00E-06 down RPL18 ribosomal protein L18 200022_at 2.00E-06 down RPL18 ribosomal protein L18 eukaryotic translation initiation factor 3, 200023_s_at 2.00E-06 down EIF3S5 subunit 5 epsilon, 47kDa eukaryotic translation initiation factor 3, 200023_s_at 2.00E-06 down EIF3S5 subunit 5 epsilon, 47kDa 200024_at 2.00E-06 down RPS5 ribosomal protein S5 200024_at 2.00E-06 down RPS5 ribosomal protein S5 200025_s_at 2.00E-06 down RPL27 ribosomal protein L27 200025_s_at 2.00E-06 down RPL27 ribosomal protein L27 200026_at 2.00E-06 down RPL34 ribosomal protein L34 200026_at 2.00E-06 down RPL34 ribosomal protein L34 200027_at 2.00E-06 down NARS asparaginyl-tRNA synthetase 200027_at 4.00E-06 down NARS asparaginyl-tRNA synthetase 200028_s_at 2.00E-06 down STARD7 START domain containing 7 200028_s_at 2.00E-06 down STARD7 START domain containing 7 200029_at 2.00E-06 down RPL19 ribosomal protein L19 200029_at 2.00E-06 down RPL19 ribosomal protein L19 solute carrier family 25 (mitochondrial 200030_s_at 2.00E-06 down SLC25A3 carrier; phosphate carrier), member 3 solute carrier family 25 (mitochondrial 200030_s_at 9.60E-05 down SLC25A3 carrier; phosphate carrier), member 3 200031_s_at 2.00E-06 down RPS11 ribosomal protein S11 200031_s_at 2.00E-06 down RPS11 ribosomal protein S11 200032_s_at 2.00E-06 down RPL9 ribosomal protein L9 200032_s_at 2.00E-06 down RPL9 ribosomal protein L9 200034_s_at 2.00E-06 down RPL6 ribosomal protein L6 200034_s_at 2.00E-06 down RPL6 ribosomal protein L6 200036_s_at 2.00E-06 down RPL10A ribosomal protein L10a 200036_s_at 2.00E-06 down RPL10A ribosomal protein L10a chromobox homolog 3 (HP1 gamma 200037_s_at 0.000716 down CBX3 homolog, Drosophila) 200038_s_at 2.00E-06 down RPL17 ribosomal protein L17 200038_s_at 2.00E-06 down RPL17 ribosomal protein L17 proteasome (prosome, macropain) 200039_s_at 3.80E-05 down PSMB2 subunit, beta type, 2 200041_s_at 0.000479 down BAT1 HLA-B associated transcript 1 200042_at 8.90E-05 down HSPC117 hypothetical protein HSPC117 200042_at 0.000676 down HSPC117 hypothetical protein HSPC117 enhancer of rudimentary homolog 200043_at 1.80E-05 down ERH (Drosophila) enhancer of rudimentary homolog 200043_at 2.80E-05 down ERH (Drosophila) 200050_at 2.00E-06 down ZNF146 zinc finger protein 146 200050_at 9.00E-06 down ZNF146 zinc finger protein 146 interleukin enhancer binding factor 2, 200052_s_at 2.00E-06 down ILF2 45kDa interleukin enhancer binding factor 2, 200052_s_at 5.00E-05 down ILF2 45kDa 200054_at 0.000485 down ZNF259 zinc finger protein 259 non-POU domain containing, octamer- 200057_s_at 2.00E-06 down NONO binding non-POU domain containing, octamer- 200057_s_at 2.00E-06 down NONO binding 200058_s_at 9.50E-05 down U5-200KD U5 snRNP-specific protein, 200-KD 200058_s_at 0.00039 down U5-200KD U5 snRNP-specific protein, 200-KD RNA binding protein S1, serine-rich 200060_s_at 2.00E-06 down RNPS1 domain RNA binding protein S1, serine-rich 200060_s_at 7.00E-06 down RNPS1 domain 200061_s_at 2.00E-06 down RPS24 ribosomal protein S24 200061_s_at 2.00E-06 down RPS24 ribosomal protein S24 200062_s_at 2.00E-06 down RPL30 ribosomal protein L30 200062_s_at 2.00E-06 down RPL30 ribosomal protein L30 nucleophosmin (nucleolar 200063_s_at 2.00E-06 down NPM1 phosphoprotein B23, numatrin) nucleophosmin (nucleolar 200063_s_at 2.00E-06 down NPM1 phosphoprotein B23, numatrin) 200067_x_at 9.80E-05 up SNX3 sorting nexin 3 200068_s_at 3.90E-05 down CANX calnexin 200068_s_at 0.000313 down CANX calnexin squamous cell carcinoma antigen 200069_at 4.00E-06 down SART3 recognised by T cells 3 squamous cell carcinoma antigen 200069_at 0.000177 down SART3 recognised by T cells 3 heterogeneous nuclear ribonucleoprotein D (AU-rich element 200073_s_at 2.00E-06 down HNRPD RNA binding protein 1, 37kDa) 200074_s_at 2.00E-06 down RPL14 ribosomal protein L14 200074_s_at 2.00E-06 down RPL14 ribosomal protein L14 200081_s_at 2.00E-06 down 200081_s_at 2.00E-06 down 200082_s_at 2.00E-06 down RPS7 ribosomal protein S7 200082_s_at 2.00E-06 down RPS7 ribosomal protein S7 200084_at 0.000965 down SMAP small acidic protein cytochrome c oxidase subunit IV 200086_s_at 7.70E-05 down COX4I1 isoform 1 cytochrome c oxidase subunit IV 200086_s_at 0.000548 down COX4I1 isoform 1 200088_x_at 2.00E-06 down RPL12 ribosomal protein L12 200088_x_at 2.00E-06 down RPL12 ribosomal protein L12 200089_s_at 2.00E-06 down RPL4 ribosomal protein L4 200089_s_at 2.00E-06 down RPL4 ribosomal protein L4 200090_at 0.000112 down FNTA farnesyltransferase, CAAX box, alpha 200091_s_at 2.00E-06 down RPS25 ribosomal protein S25 200091_s_at 0.000128 down RPS25 ribosomal protein S25 200092_s_at 2.00E-06 down RPL37 ribosomal protein L37 200092_s_at 3.80E-05 down RPL37 ribosomal protein L37 histidine triad nucleotide binding 200093_s_at 4.00E-06 down HINT1 protein 1 histidine triad nucleotide binding 200093_s_at 3.80E-05 down HINT1 protein 1 eukaryotic translation elongation factor 200094_s_at 2.00E-06 down EEF2 2 eukaryotic translation elongation factor *probe sets 200094_s_at 2.00E-06 down EEF2 2 200000_s_at - 200095_x_at 2.00E-06 down RPS10 ribosomal protein S10 200099_s_at are present on 200095_x_at 2.00E-06 down RPS10 ribosomal protein S10 both Human U133-A chip and 200098_s_at 2.00E-06 down ANAPC5 anaphase promoting complex subunit 5 U133-B chip. Therefore these 200098_s_at 2.00E-06 down ANAPC5 anaphase promoting complex subunit 5 probes are 200099_s_at 2.00E-06 down RPS3A ribosomal protein S3A measured twice 200099_s_at 2.00E-06 down RPS3A ribosomal protein S3A for each sample. eukaryotic translation initiation factor 3, 200595_s_at 4.70E-05 down EIF3S10 subunit 10 theta, 150/170kDa eukaryotic translation initiation factor 3, 200596_s_at 4.00E-06 down EIF3S10 subunit 10 theta, 150/170kDa 200599_s_at 0.00012 down TRA1 tumor rejection antigen (gp96) 1 200610_s_at 2.00E-06 down NCL nucleolin 200624_s_at 1.80E-05 down MATR3 matrin 3 200626_s_at 5.50E-05 down MATR3 matrin 3 200629_at 0.000553 up WARS tryptophanyl-tRNA synthetase SET translocation (myeloid leukemia- 200630_x_at 9.60E-05 down SET associated) SET translocation (myeloid leukemia- 200631_s_at 2.00E-06 down SET associated) 200634_at 2.80E-05 up PFN1 profilin 1 superoxide dismutase 1, soluble 200642_at 2.00E-06 down SOD1 (amyotrophic lateral sclerosis 1 (adult)) 200644_at 0.000459 down MLP MARCKS-like protein 200646_s_at 4.90E-05 up NUCB1 nucleobindin 1 eukaryotic translation initiation factor 3, 200647_x_at 2.00E-06 down EIF3S8 subunit 8, 110kDa 200649_at 1.90E-05 up NUCB1 nucleobindin 1 200650_s_at 4.20E-05 up LDHA lactate dehydrogenase A guanine nucleotide binding protein (G 200651_at 2.00E-06 down GNB2L1 protein), beta polypeptide 2-like 1 calmodulin 1 (phosphorylase kinase, 200655_s_at 0.000143 down CALM1 delta) solute carrier family 25 (mitochondrial carrier; adenine nucleotide 200657_at 2.00E-06 down SLC25A5 translocator), member 5 translocase of outer mitochondrial 200662_s_at 2.00E-06 down TOMM20 membrane 20
Load more

Recommended publications
  • The Diversity of Dolichol-Linked Precursors to Asn-Linked Glycans Likely Results from Secondary Loss of Sets of Glycosyltransferases
    The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases John Samuelson*†, Sulagna Banerjee*, Paula Magnelli*, Jike Cui*, Daniel J. Kelleher‡, Reid Gilmore‡, and Phillips W. Robbins* *Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 715 Albany Street, Boston, MA 02118-2932; and ‡Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, MA 01665-0103 Contributed by Phillips W. Robbins, December 17, 2004 The vast majority of eukaryotes (fungi, plants, animals, slime mold, to N-glycans of improperly folded proteins, which are retained in and euglena) synthesize Asn-linked glycans (Alg) by means of a the ER by conserved glucose-binding lectins (calnexin͞calreticulin) lipid-linked precursor dolichol-PP-GlcNAc2Man9Glc3. Knowledge of (13). Although the Alg glycosyltransferases in the lumen of ER this pathway is important because defects in the glycosyltrans- appear to be eukaryote-specific, archaea and Campylobacter sp. ferases (Alg1–Alg12 and others not yet identified), which make glycosylate the sequon Asn and͞or contain glycosyltransferases dolichol-PP-glycans, lead to numerous congenital disorders of with domains like those of Alg1, Alg2, Alg7, and STT3 (1, 14–16). glycosylation. Here we used bioinformatic and experimental Protists, unicellular eukaryotes, suggest three notable exceptions methods to characterize Alg glycosyltransferases and dolichol- to the N-linked glycosylation path described in yeast and animals PP-glycans of diverse protists, including many human patho- (17). First, the kinetoplastid Trypanosoma cruzi (cause of Chagas gens, with the following major conclusions. First, it is demon- myocarditis), fails to glucosylate the dolichol-PP-linked precursor strated that common ancestry is a useful method of predicting and so makes dolichol-PP-GlcNAc2Man9 (18).
    [Show full text]
  • Apc11 (ANAPC11) (NM 001002245) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC223841L4 Apc11 (ANAPC11) (NM_001002245) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: Apc11 (ANAPC11) (NM_001002245) Human Tagged ORF Clone Tag: mGFP Symbol: ANAPC11 Synonyms: APC11; Apc11p; HSPC214 Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC223841). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_001002245 ORF Size: 252 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Apc11 (ANAPC11) (NM_001002245) Human Tagged ORF Clone – RC223841L4 OTI Disclaimer: Due to the inherent nature of this plasmid, standard methods to replicate additional amounts of DNA in E. coli are highly likely to result in mutations and/or rearrangements. Therefore, OriGene does not guarantee the capability to replicate this plasmid DNA. Additional amounts of DNA can be purchased from OriGene with batch-specific, full-sequence verification at a reduced cost. Please contact our customer care team at [email protected] or by calling 301.340.3188 option 3 for pricing and delivery. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,780,253 Subramanian Et Al
    III USOO5780253A United States Patent 19 11 Patent Number: 5,780,253 Subramanian et al. (45) Date of Patent: Jul. 14, 1998 54 SCREENING METHOD FOR DETECTION OF 4.433.999 2/1984 Hyzak ....................................... 71.03 HERBCDES 4.6–552 2/1987 Anoti et al. if O3. 4,802,912 2/1989 Baker ........................................ 7/103 Inventors: Wenkiteswaran Subramanian Danville: Anne G. Toschi. Burlingame. OTHERTHER PPUBLICATION CATIONS both of Calif. Heim et al. Pesticide Biochem & Physiol; vol. 53, pp. 138-145 (1995). 73) Assignee: Sandoz Ltd., Basel. Switzerland Hatch. MD.: Phytochem. vol. 6... pp. 115 to 119, (1967). Haworth et al. J. Agric. Food Chem, vol. 38, pp. 1271-1273. 21 Appl. No.:752.990 1990. Nishimura et al: Phytochem: vol. 34, pp. 613-615. (1993). 22 Filed: Nov. 21, 1996 Primary Examiner-Louise N. Leary Related U.S. Application Data Attorney, Agent, or Firm-Lynn Marcus-Wyner: Michael P. Morris 63 Continuation of Ser. No. 434.826, May 4, 1995, abandoned. 6 57 ABSTRACT 51 Int. Cl. ............................... C12Q 1/48: C12Q 1/32: C12Q 1/37; C12O 1/00 This invention relates to novel screening methods for iden 52 U.S. Cl. ................................. 435/15:435/18: 435/26: tifying compounds that specifically inhibit a biosynthetic 435/23: 435/4, 536/23.6:536/23.2:536/24.3 pathway in plants. Enzymes which are specifically affected 536/26.11:536/26.12:536/26.13 by the novel screening method include plant purine biosyn 58 Field of Search .................................. 435/15, 8, 26, thetic pathway enzymes and particularly the enzymes 435/23 4: 536/23.6, 23.2, 24.3, 26.1, involved in the conversion of inosine monophosphate to 26.12, 26.13 adenosine monophosphate and inosine monophosphate to guanosine monophosphate.
    [Show full text]
  • ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody – AP08962PU-N
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AP08962PU-N ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: ELISA, IHC, WB Recommended Dilution: ELISA: 1/32000. Immunohistochemistry on Paraffin Sections: 3.75 µg/ml. Western Blot: 1 - 3 µg/ml. Reactivity: Canine, Human Host: Goat Clonality: Polyclonal Immunogen: Synthetic peptide from C-terminus of human ALS2CR2 Specificity: This antibody reacts to STE20-Related Kinase Adaptor Beta (STRADB/ALS2CR2) at aa 406-418. It is expected to recognise both human isoforms: ILPIP-alpha (NP_061041.2) and ILPIP-beta (AAF71042.1). Formulation: Tris saline buffer, pH 7.3, 0.5% BSA, 0.02% sodium azide State: Aff - Purified State: Liquid purified Ig Concentration: lot specific Purification: Immunoaffinity Chromatography Conjugation: Unconjugated Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. Database Link: Entrez Gene 55437 Human Q9C0K7 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody – AP08962PU-N Background: Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2, is connected to transferase/kinase activity and ATP binding, it has recently been shown to interact with XIAP, a member of the IAP (Inhibitor of Apoptosis) protein family.
    [Show full text]
  • Physical Interactions Between the Alg1, Alg2, and Alg11 Mannosyltransferases of the Endoplasmic Reticulum
    Glycobiology vol. 14 no. 6 pp. 559±570, 2004 DOI: 10.1093/glycob/cwh072 Advance Access publication on March 24, 2004 Physical interactions between the Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticulum Xiao-Dong Gao2, Akiko Nishikawa1, and Neta Dean1 begins on the cytosolic face of the ER, where seven sugars (two N-acetylglucoseamines and five mannoses) are added 1Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York, Stony Brook, sequentially to dolichyl phosphate on the outer leaflet of NY 11794-5215, and 2Research Center for Glycoscience, National the ER, using nucleotide sugar donors (Abeijon and Institute of Advanced Industrial Science and Technology, Tsukuba Hirschberg, 1992; Perez and Hirschberg, 1986; Snider and Downloaded from https://academic.oup.com/glycob/article/14/6/559/638968 by guest on 30 September 2021 Central 6, 1-1 Higashi, Tsukuba 305-8566, Japan Rogers, 1984). After a ``flipping'' or translocation step, the Received on January 26, 2004; revised on March 2, 2004; accepted on last seven sugars (four mannoses and three glucoses) are March 2, 2004 added within the lumen of the ER, using dolichol-linked sugar donors (Burda and Aebi, 1999). Once assembled, the The early steps of N-linked glycosylation involve the synthesis oligosaccharide is transferred from the lipid to nascent of a lipid-linked oligosaccharide, Glc3Man9GlcNAc2-PP- protein in a reaction catalyzed by oligosaccharyltransferase. dolichol, on the endoplasmic reticulum (ER) membrane. After removal of terminal glucoses and a single mannose, Prior to its lumenal translocation and transfer to nascent nascent glycoproteins bearing the N-linked Man8GlcNAc2 glycoproteins, mannosylation of Man5GlcNAc2-PP-dolichol core can exit the ER to the Golgi, where this core may is catalyzed by the Alg1, Alg2, and Alg11 mannosyltrans- undergo further carbohydrate modifications.
    [Show full text]
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • The Role and Mechanisms of Action of Micrornas in Cancer Drug Resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6*
    Si et al. Clinical Epigenetics (2019) 11:25 https://doi.org/10.1186/s13148-018-0587-8 REVIEW Open Access The role and mechanisms of action of microRNAs in cancer drug resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6* Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can regulate various target genes and are thus involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. Drug resistance in cancer chemotherapy is one of the main obstacles to curing this malignant disease. Statistical data indicate that over 90% of the mortality of patients with cancer is related to drug resistance. Drug resistance of cancer chemotherapy can be caused by many mechanisms, such as decreased antitumor drug uptake, modified drug targets, altered cell cycle checkpoints, or increased DNA damage repair, among others. In recent years, many studies have shown that miRNAs are involved in the drug resistance of tumor cells by targeting drug-resistance-related genes or influencing genes related to cell proliferation, cell cycle, and apoptosis. A single miRNA often targets a number of genes, and its regulatory effect is tissue-specific. In this review, we emphasize the miRNAs that are involved in the regulation of drug resistance among different cancers and probe the mechanisms of the deregulated expression of miRNAs. The molecular targets of miRNAs and their underlying signaling pathways are also explored comprehensively. A holistic understanding of the functions of miRNAs in drug resistance will help us develop better strategies to regulate them efficiently and will finally pave the way toward better translation of miRNAs into clinics, developing them into a promising approach in cancer therapy.
    [Show full text]
  • Supporting Online Material
    1 2 3 4 5 6 7 Supplementary Information for 8 9 Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic 10 retinopathy 11 12 *Samuel A. Mills, *Andrew I. Jobling, *Michael A. Dixon, Bang V. Bui, Kirstan A. Vessey, Joanna A. Phipps, 13 Ursula Greferath, Gene Venables, Vickie H.Y. Wong, Connie H.Y. Wong, Zheng He, Flora Hui, James C. 14 Young, Josh Tonc, Elena Ivanova, Botir T. Sagdullaev, Erica L. Fletcher 15 * Joint first authors 16 17 Corresponding author: 18 Prof. Erica L. Fletcher. Department of Anatomy & Neuroscience. The University of Melbourne, Grattan St, 19 Parkville 3010, Victoria, Australia. 20 Email: [email protected] ; Tel: +61-3-8344-3218; Fax: +61-3-9347-5219 21 22 This PDF file includes: 23 24 Supplementary text 25 Figures S1 to S10 26 Tables S1 to S7 27 Legends for Movies S1 to S2 28 SI References 29 30 Other supplementary materials for this manuscript include the following: 31 32 Movies S1 to S2 33 34 35 36 1 1 Supplementary Information Text 2 Materials and Methods 3 Microglial process movement on retinal vessels 4 Dark agouti rats were anaesthetized, injected intraperitoneally with rhodamine B (Sigma-Aldrich) to label blood 5 vessels and retinal explants established as described in the main text. Retinal microglia were labelled with Iba-1 6 and imaging performed on an inverted confocal microscope (Leica SP5). Baseline images were taken for 10 7 minutes, followed by the addition of PBS (10 minutes) and then either fractalkine or fractalkine + candesartan 8 (10 minutes) using concentrations outlined in the main text.
    [Show full text]
  • The Endocytic Membrane Trafficking Pathway Plays a Major Role
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Liverpool Repository RESEARCH ARTICLE The Endocytic Membrane Trafficking Pathway Plays a Major Role in the Risk of Parkinson’s Disease Sara Bandres-Ciga, PhD,1,2 Sara Saez-Atienzar, PhD,3 Luis Bonet-Ponce, PhD,4 Kimberley Billingsley, MSc,1,5,6 Dan Vitale, MSc,7 Cornelis Blauwendraat, PhD,1 Jesse Raphael Gibbs, PhD,7 Lasse Pihlstrøm, MD, PhD,8 Ziv Gan-Or, MD, PhD,9,10 The International Parkinson’s Disease Genomics Consortium (IPDGC), Mark R. Cookson, PhD,4 Mike A. Nalls, PhD,1,11 and Andrew B. Singleton, PhD1* 1Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 2Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain 3Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 4Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 5Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 6Department of Pathophysiology, University of Tartu, Tartu, Estonia 7Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 8Department of Neurology, Oslo University Hospital, Oslo, Norway 9Department of Neurology and Neurosurgery, Department of Human Genetics, McGill University, Montréal, Quebec, Canada 10Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada 11Data Tecnica International, Glen Echo, Maryland, USA ABSTRACT studies, summary-data based Mendelian randomization Background: PD is a complex polygenic disorder.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Design and Methods of the Prevalence and Pharmacogenomics of Tenofovir Nephrotoxicity in HIV-Positive Adults in South-Western Nigeria Study Muzamil O
    Hassan et al. BMC Nephrology (2020) 21:436 https://doi.org/10.1186/s12882-020-02082-3 STUDY PROTOCOL Open Access Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study Muzamil O. Hassan1,2* , Raquel Duarte3, Victor O. Mabayoje4, Caroline Dickens3, Akeem O. Lasisi5 and Saraladevi Naicker6 Abstract Background: Individuals of African descent are at higher risk of developing kidney disease than their European counterparts, and HIV infection is associated with increased risk of nephropathy. Despite a safe renal profile in the clinical trials, long-term use of tenofovir disoproxil fumarate (TDF) has been associated with proximal renal tubulopathy although the underlying mechanisms remain undetermined. We aim to establish the prevalence of and risk factors for TDF-induced kidney tubular dysfunction (KTD) among HIV-I and II individuals treated with TDF in south-west Nigeria. Association between TDF-induced KTD and genetic polymorphisms in renal drug transporter genes and the APOL1 (Apolipoprotein L1) gene will be examined. Methods: This study has two phases. An initial cross-sectional study will screen 3000 individuals attending the HIV clinics in south-west Nigeria for KTD to determine the prevalence and risk factors. This will be followed by a case- control study of 400 KTD cases and 400 matched controls to evaluate single nucleotide polymorphism (SNP) associations. Data on socio-demographics, risk factors for kidney dysfunction and HIV history will be collected by questionnaire. Blood and urine samples for measurements of severity of HIV disease (CD4 count, viral load) and renal function (creatinine, eGFR, phosphate, uric acid, glucose) will also be collected.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]